Covance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award

Covance, the world's most comprehensive drug development company and a leader in nutritional analysis, recently announced that it has been awarded the 2014 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award, based on the company’s strong business performance and continued investments in the Asia Pacific region. The award was presented to Covance at the Frost & Sullivan Asia Pacific Best Practice Awards ceremony in Singapore last night.

Over the past several years, Covance expanded its central laboratory and nutritional chemistry laboratory facilities in Singapore, added to its preclinical and clinical footprint in China, and significantly grew its clinical operations in China, Japan, Korea and other Asia Pacific countries to meet growing demand in the region for both regional and global trials. Partnering with Covance in Asia Pacific allows clients to access its capabilities in this region and also provides the gateway for local and regional pharmaceutical companies to access global markets.

“To meet present and future drug development requirements, and to tap the fast growing opportunities in Asia Pacific region, Covance expanded its investments in its clinical and preclinical business areas. Covance has shown strong growth and has emerged as a leader in the rapidly growing Asia Pacific CRO market. With its strong overall performance, Covance has earned Frost & Sullivan’s 2014 Growth Excellence Leadership Award,” said Sanjeev Kumar, Consultant, Healthcare Practice Asia Pacific, Frost & Sullivan.

“This award further validates the significance of our investments in our late-stage and early development service lines in the Asia Pacific region and acknowledges our leadership position in the CRO industry” said Nick Wright, Vice President & General Manager, Phase II-IV Clinical Development Asia Pacific, at Covance. “Covance is the only CRO in the region with the expertise to develop a molecule from discovery through all preclinical and clinical milestone and we’re very committed to continue bringing our Asia Pacific clients solutions that advance drug development.”

About Covance
Covance, the world's most comprehensive drug development company and a leader in nutritional analysis, is dedicated to advancing healthcare and delivering Solutions Made Real. The Company, headquartered in Princeton, New Jersey, has annual revenues greater than $2.4B and more than 12,500 employees located in over 60 countries. For more information, visit www.covance.com.

About the 2014 Frost & Sullivan Asia Pacific Best Practices Awards
Now in its seventh consecutive year, the Frost & Sullivan Asia Pacific Best Practices Awards recognize companies across industries commending their diligence, commitment, and innovative business strategies required to advance in the global marketplace. Exemplary companies across different industries and functional disciplines in the region will be recognized in the following categories: environment, energy & power, industrial, chemicals, logistics, healthcare and IT. Frost & Sullivan follows a rigorous measurement based methodology based on actual market performance indicators to select the recipients in each category.